Developments Urovant Sciences vibegron fails Phase 2a IBS trial Urovant Sciences (NASDAQ:UROV) reported disappointing topline results from its Phase 2b trial of vibegron for the treatment of abdominal pain due to irritable bowel syndrome (IBS) in women. The study failed to meet its... November 25, 2020